Production Method 1

33631-05-9

896139-85-8

Reaction Conditions

1.1 Solvents: Ethanol ,  Water ;  overnight, reflux

Reference

Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities

Xi, Jian-Bei; Fang, Yan-Fen; Frett, Brendan; Zhu, Meng-Li; Zhu, Tong; et al, European Journal of Medicinal Chemistry, 2017, 126, 1083-1106

Production Method 2

808744-34-5

896139-85-8

Reaction Conditions

1.1 Reagents: Lithium hydroxide Catalysts: Copper(II) acetylacetonate ,  N1,N2-Bis(4-hydroxy-2,6-dimethylphenyl)ethanediamide ;  rt
1.2 Solvents: Dimethyl sulfoxide ,  Water ;  24 h, 80 °C
1.3 Reagents: Hydrochloric acid Solvents: Water ;  acidified, cooled

Reference

Copper-Catalyzed Hydroxylation of (Hetero)aryl Halides under Mild Conditions

Xia, Shanghua; Gan, Lu; Wang, Kailiang; Li, Zheng; Ma, Dawei, Journal of the American Chemical Society, 2016, 138(41), 13493-13496

Imidazo[1,2-a]pyridin-7-ol Raw materials

• 7-Bromoimidazo[1,2-a]pyridine
• 2-Aminopyridin-4-ol

Imidazo[1,2-a]pyridin-7-ol Preparation Products

• Imidazo[1,2-a]pyridin-7-ol (896139-85-8)

• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Enantiomerically pure 1,3,2-dioxaborolanes: new reagents for the hydroboration of alkynes
  Chem. Commun., 1998, 2651-2652
• 4. Disulfide- and terminal alkyne-functionalized magnetic silica particles for enrichment of azido glycopeptides?
  Sheng Wang,Wenxian Xie,Xiu Zhang,Xia Zou,Yan Zhang Chem. Commun., 2012,48, 5907-5909
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Recent Advances in the Study of Imidazo[1,2-a]pyridin-7-ol (CAS: 896139-85-8) in Chemical Biology and Pharmaceutical Research

The compound Imidazo[1,2-a]pyridin-7-ol (CAS: 896139-85-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile pharmacological properties and potential therapeutic applications. This heterocyclic scaffold is a key structural motif in various bioactive molecules, exhibiting a broad spectrum of biological activities, including antimicrobial, anticancer, and anti-inflammatory effects. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its potential as a lead compound for drug development.

One of the most notable advancements in this area is the discovery of Imidazo[1,2-a]pyridin-7-ol derivatives as potent inhibitors of specific kinase targets involved in cancer progression. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that certain derivatives of this compound exhibit high selectivity and efficacy against tyrosine kinase receptors, which are often overexpressed in various malignancies. The study utilized molecular docking and in vitro assays to validate the binding affinity and inhibitory effects of these derivatives, paving the way for further preclinical evaluations.

In addition to its anticancer potential, Imidazo[1,2-a]pyridin-7-ol has also been investigated for its role in modulating inflammatory pathways. A recent publication in Bioorganic & Medicinal Chemistry Letters highlighted its ability to suppress the production of pro-inflammatory cytokines by targeting key signaling molecules such as NF-κB and MAPK. These findings suggest that this compound could serve as a promising candidate for the development of novel anti-inflammatory therapeutics, particularly for chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.

From a synthetic chemistry perspective, researchers have made significant strides in optimizing the production of Imidazo[1,2-a]pyridin-7-ol and its derivatives. A 2022 study in Organic Letters reported a novel, high-yield synthetic route using palladium-catalyzed cross-coupling reactions, which significantly improved the scalability and purity of the compound. This methodological advancement is expected to facilitate further pharmacological studies and accelerate the translation of these findings into clinical applications.

Despite these promising developments, challenges remain in the clinical translation of Imidazo[1,2-a]pyridin-7-ol-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through comprehensive pharmacokinetic and toxicological studies. However, the growing body of research underscores the potential of this compound as a versatile scaffold for drug discovery, with applications spanning oncology, immunology, and infectious diseases.

In conclusion, the recent studies on Imidazo[1,2-a]pyridin-7-ol (CAS: 896139-85-8) highlight its significant potential in chemical biology and pharmaceutical research. The compound's diverse biological activities, coupled with advancements in synthetic methodologies, position it as a valuable candidate for further investigation. Future research should focus on addressing the remaining challenges and exploring its full therapeutic potential in various disease contexts.

• 1187932-09-7(2-Amino-4-hydroxypyridine hydrochloride)
• 1785060-31-2(2-Aminoimidazo[1,2-a]pyridin-7-ol)
• 33631-05-9(2-Aminopyridin-4-ol)
• 99845-76-8(2,6-diamino-4-Pyridinol)
• 49582-46-9(4,4-Bis(dimethylamino)-3-buten-2-one)
• 40347-20-4(4-(Dimethylamino)-4-(methylamino)but-3-en-2-one)
• 91860-01-4(1H-Imidazolium, 1-methyl-3-(3-oxo-1-butenyl)-, iodide)
• 1243476-30-3(2-(Methylamino)pyridin-4-OL)
• 1240599-30-7(2-Dimethylaminopyridin-4-ol)
• 33623-18-6(4(1H)-Pyridinone,2-amino-)